MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Market Cap 2011-2026 | VIVO
As of March 27, 2026 Meridian Bioscience has a market cap of $ 1.49 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.35 B | 865 M | 771 M | 415 M | 680 M | 591 M | 631 M | 696 M | 647 M | 832 M | 638 M | 564 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.35 B | 415 M | 723 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
42 B | $ 111.16 | -2.04 % | $ 33.8 B |  USA |
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
4.75 B | $ 13.26 | -2.07 % | $ 3.77 B | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
|
Biodesix
BDSX
|
92.1 M | $ 14.28 | -2.19 % | $ 1.85 B | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
7.95 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 16.25 | -12.16 % | $ 175 M |  China |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 24.03 | -2.71 % | $ 667 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 158.22 | -4.18 % | $ 7.84 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 196.67 | -0.75 % | $ 21.8 B | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
32.8 M | $ 8.45 | - | $ 33.7 M | Israel |
 |
DexCom
DXCM
|
25.5 B | $ 62.38 | -5.61 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 15.72 | -4.06 % | $ 475 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 84.78 | -3.77 % | $ 10.6 B | USA |
 |
PerkinElmer
PKI
|
14.1 B | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 102.7 | -0.37 % | $ 8.47 B |  Irlanda |
 |
Illumina
ILMN
|
16.4 B | $ 118.42 | -4.81 % | $ 18.8 B | USA |
 |
Interpace Biosciences
IDXG
|
4.12 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 165.13 | -2.52 % | $ 28.4 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 74.66 | -2.23 % | $ 5.04 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
13 B | $ 455.39 | -2.4 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 240.08 | -2.36 % | $ 25.6 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.43 | -4.22 % | $ 410 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.2 M | $ 4.7 | 2.4 % | $ 2.52 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 7.55 | -2.77 % | $ 967 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 8.85 | -3.33 % | $ 1.92 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 17.23 | -0.78 % | $ 386 M | USA |
 |
Celcuity
CELC
|
5.37 B | $ 108.87 | -5.06 % | $ 5.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |